Access to antiretrovirals in developing countries: towards a new landscape?
5 October 2011
10:00 to 12:30
Centre de Conférences Varembé (CCV)
This event has now passed. To browse our upcoming events click here.
The HIV/AIDS epidemic has profoundly changed the global health debate. Governments, International Organizations, NGOs and the private sector have all had to think of new ways to operate in order to ensure that patients receive the healthcare they need. The introduction of new antiretrovirals (ARVs) has led to a dramatic reduction in the mortality rate of patients. However, ensuring these medicines reach those who need them continues to raise complex questions in terms of logistics, healthcare infrastructure, awareness raising and financing. Now, 10 years after the Doha Declaration on the TRIPS Agreement and Public Health, it is a good moment to review the major achievements and challenges in the fight against HIV/AIDS. In this context, the IFPMA held a discussion on the findings of recent research on the changes in the landscape on access to ARVs.
Introduction & Welcome
Andrew Jenner / Director, Intellectual Property
and Trade, IFPMA
Presentation of the Research
Tim Wilsdon / Vice President,
Charles River Associates
Brenda Waning / Coordinator,
Market Dynamics, UNITAID
Mariângela Simão / Chief, Prevention,
Vulnerability & Rights Division, Evidence Strategy
& Results Department, UNAIDS
Daphne Mlotshwa / Minister Counselor,
Permanent Mission of Botswana
Jon Pender / VP, IP & Access, Global Health,
Government Affairs, Public Policy and Patient
William New is Director and Editor-in-Chief of Intellectual Property Watch, a highly regarded
independent reporting service based in Geneva, Switzerland. Intellectual Property Watch
covers international policymaking relating to IPR, innovation, trade, public health, food
security, internet governance, environment and a range of other issues. Previously, he was
a senior writer for Washington-based National Journal Group, including Technology Daily
and CongressDaily, and a senior reporter at Washington-based Inside U.S. Trade and
managing editor of Americas Trade. Earlier in his career, William worked at the Georgetown
University School of Foreign Service, following a national MBA fellowship in public policy at
Georgetown. William frequently chairs or speaks on panels, and expert appearances on
television and radio have included CNBC, National Public Radio, and C-SPAN’s Washington
Journal. William holds an MA in Latin American Economics and Political Science, and an
international MBA from the University of New Mexico, as well as a BA in Literature from
Tim Wilsdon is a Vice President in the London office of Charles River Associates. Over the
last fifteen years, Tim has worked on policy focused projects involving the Life Sciences
industry. This includes studies for European Commission (including DG Enterprise, DG
Internal markets and DG Sanco), and the pharmaceutical industry (through EFPIA, PhRMA,
and country associations such as ABPI, LIF, and PIASA) on how pharmaceutical markets
could be reformed to work more efficiently. He was responsible for leading an assignment
for the European Commission determining whether there was a global crisis in innovation.
He commonly talks at European conferences on issues to do with pricing and
reimbursement and the economics of innovation.
Brenda Waning recently assumed the role of Coordinator of Market Dynamics at UNITAID, a
WHO-partnership based in Geneva. She leads UNTAID’s technical team responsible for
monitoring trends in HIV/AIDS, tuberculosis, and malaria markets and assessing the public
health and market impact of UNITAID’s interventions. Prior to joining UNITAID, Brenda
served as Director of Pharmaceutical Policy at Boston University School of Medicine where
she authored numerous peer-reviewed studies on pharmaceutical policy at local, national,
and global levels. Her most recent work includes the creation of a large market intelligence
database on antiretroviral medicines that she uses to evaluate impacts of global policy on
market evolution and access to antiretroviral medicines.
Mariângela Simão was the director of the Department of STD and AIDS, Ministry of Health,
Brazil, from April 2006 to July 2010. Since 1982 she has worked in the Brazilian public
health system, from the primary health care level to a series of managerial positions
throughout the years. As a public health professional, at municipal, state and national levels,
she played an active role in the decentralization of the national health system, acquiring an
extensive experience in health system strengthening. She has also served on the boards of
a number of organizations and government committees related to public health and
Heading the National STD/Aids Department (including Viral Hepatitis from 2009), she had
the responsibility of overseeing and implementing the national STD/AIDS/Viral Hepatitis
policies, including universal and free of charge access to treatment, care and
comprehensive prevention programs.
She currently works at UNAIDS Secretariat in Geneva, heading the Prevention, Vulnerability
and Rights Division.
Dr. Simão attended medical school in Brazil, with degrees in Paediatrics and Public Health,
and a MSc in Mother and Child Health in the UK.
After graduating from the University of Botswana in 1995 with a BA in Public Administration
and Economics, Miss Mlotshwa joined the Ministry of Foreign Affairs and International
Cooperation of Botswana, where she has held a number of posts. From 1997 to 2002 she
was at the Botswana Mission in South Africa, later moving to the Botswana Mission in New
York, where she covered Second Committee issues at the United Nations from 2002 to
2004. She then moved to the Botswana Mission in Namibia, returning home in 2006 where,
still with the Ministry of Foreign Affairs and International Cooperation, she worked as
Assistant Director on the Africa and the Middle East Desk, and then joined the Public
Relations, Research and Information Department as Deputy Director.
Miss Mlotshwa now lives in Geneva with her three children and is the Minister Counsellor at
the Permanent Mission of the Republic of Botswana to the United Nations Office and other
International Organisations at Geneva, focusing on Health issues, amongst others.
Jon Pender is Vice President, IP & Access, Global Health in GSK’s Government Affairs
Department. As such, he is responsible for ensuring that GSK’s approach to sustainably
improving access to medicines in the developing world reaches as many people in need as
possible, whilst protecting the fundamental business model which underpins the researchbased
Jon has participated in a number of hearings, workshops, seminars, evidence sessions and
other events on access to medicines and partnership issues including at the UK Parliament,
European Parliament and Commission, UN, World Bank, WTO and the WHO.
Jon works with a wide-range of stakeholders including governments, NGOs, multilateral
agencies, investors and the media, and represents GSK at a number of international
organisations such as the WHO and WTO. He also regularly attends the Board Meetings of
the Global Fund to Fight AIDS TB and Malaria and is an Alternate Board Member for the
Private Sector at the Roll Back Malaria Board. He is Chair of the CBI’s WTO Working Group
and the IFPMA’s Global Health Committee and co-Chairs the UK’s Industry Government
Forum on Access to Medicines (IGFAM).
Andrew Jenner is Director of Innovation, Intellectual Property (IP) & Trade at the
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). He is
responsible for developing pharmaceutical industry strategy on Intellectual Property policy
and represents the industry on IP and trade related issues within the UN and the World
Trade Organization. He also leads a team of policy experts on trade, biotherapeutics and
From 2007 until 2009 he was a Senior Policy Advisor and Head of the IP Crime Policy
Group for the UK Intellectual Property Office (IPO), bringing together Government
departments, Enforcement agencies and Industry to combat Intellectual Property Crime.
From 2004 – 2007 he was Head of Trade & Development at the IPO and lead the IP
discussions within the World Trade Organization (WTO), the World Health Organization
(WHO) and World Intellectual Property Organization’s (WIPO) Intergovernmental Committee
on genetic resources. He also led on policy relating to EU/UK IP pharmaceutical regulations,
including negotiating the EU Regulation on the compulsory licensing of pharmaceutical
products for export, and implementation of the EU ‘bolar exemption’ and Paediatric
Medicines Regulation into UK law.
He first joined the UK Government in 1998 as a patent examiner having previously worked
in the automotive industry as a quality control advisor.
He remains a member of the Institute of Engineering and Technology having a Bachelor
degree in Engineering and a Master of Laws.